Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma-A Retrospective Multicenter...

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Multiple myeloma (MM) therapies yield deep responses but rarely achieve durable remissions, with most patients eventually relapsing.
• Allogeneic hematopoietic stem cell transplantation (allo-SCT) is an established MM treatment, but often associated with short-lived responses and significant toxicity.
• Allo-SCT presents a valuable platform for integrating novel immunotherapies to enhance clinical outcomes in MM.

Purpose of the Study:

• To characterize the outcomes of refractory multiple myeloma patients undergoing allo-SCT.
• To identify factors associated with durable remissions after allo-SCT in MM.
• To evaluate the long-term efficacy and safety of allo-SCT in heavily pretreated MM.

Main Methods:

• Retrospective analysis of 128 refractory MM patients who underwent allo-SCT across five German centers (2010-2021).
• Assessment of progression-free survival (PFS), overall survival (OS), and non-relapse mortality (NRM).
• Statistical analysis to determine significant prognostic variables, including pre-transplant complete response (CR).

Main Results:

• Median PFS and OS were 7 and 19 months, respectively, with a median follow-up of 6.4 years.
• 6-year NRM was 28%. 1, 2, and 6-year OS rates were 61%, 49%, and 38%, respectively.
• Achieving CR before allo-SCT was the most significant predictor of favorable outcomes.

Conclusions:

• Allo-SCT remains a viable option for select fit patients with refractory MM, offering potentially curative potential.
• Patient selection based on pre-transplant status, particularly CR, is critical for maximizing allo-SCT benefits and minimizing toxicity.
• Further research should focus on identifying characteristics predictive of durable responses to personalize MM treatment strategies.